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A B S T R A C TObjectives: Patient-reported outcomes assessing multiple gastroin-
testinal symptoms are central to characterizing the therapeutic
benefit of novel agents for irritable bowel syndrome (IBS). Common
approaches that sum or average responses across different illness
components must be unidimensional and have small unique var-
iances to avoid aggregation bias and misinterpretation of clinical data.
This study sought to evaluate the unidimensionality of the IBS
Symptom Severity Scale (IBS-SSS) and to explore person-centered
cluster analytic methods for characterizing multivariate-based patient
profiles. Methods: Ninety-eight Rome-diagnosed patients with IBS
completed the IBS-SSS and a single, global item of symptom severity
(UCLA Symptom Severity Scale) at pretreatment baseline of a clinical
trial funded by the National Institutes of Health. k-means cluster
analyses were performed on participants’ symptom severity scores.
Results: The IBS-SSS was not unidimensional. Exploratory cluster
analyses revealed four common symptom profiles across five items of
the IBS-SSS. One cluster of patients (25%) had elevated scores on pain
frequency and bowel dissatisfaction, with less elevated but still highsee front matter Copyright & 2013, International S
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.1016/j.jval.2012.08.2207
pinions expressed in this article are those of the a
thors (JML, CB) are members.
buffalo.edu.
ndence to: Jeffrey M. Lackner, Division of Gastroen
MC, 462 Grider Street, Buffalo, NY 14215, USA.scores on life interference and low pain severity ratings. A second
cluster (19%) was characterized by intermediate scores on both pain
dimensions but more elevated scores on bowel dissatisfaction. A third
cluster (18%) had elevated scores across all IBS-SSS subcomponents.
The fourth and the most common cluster (37%) had relatively low
scores on all dimensions except bowel dissatisfaction and life inter-
ference due to IBS symptoms. Conclusions: Patient-reported outcome
end points and research on IBS more generally relying on multi-
component assessments of symptom severity should take into
account the multidimensional structure of symptoms to avoid aggre-
gation bias and to optimize the sensitivity of detecting treatment
effects.
Keywords: disease severity, global assessment, health status
indicators, outcome research, psychometric properties,
questionnaire development, rating scale.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Irritable bowel syndrome (IBS) is a chronic often times disabling
gastrointestinal (GI) condition characterized by abdominal pain
associated with altered bowel habits (diarrhea, constipation, or
both in an alternating manner). With a worldwide prevalence of
10% to 15% [1], IBS imposes a considerable burden on both the
individual sufferer and the society as a whole [2,3]. There is
currently no satisfactory medical treatment for the full range of
symptoms of IBS. Two of the past three drug therapies approved
by the Food and Drug Administration (FDA) for the treatment of
IBS have required regulatory intervention, leading to drug with-
drawal in one case and a severely restrictive risk management
program in the other. These events, coupled with recent FDA
restrictions on the primary study end point to be used in IBS
pharmaceutical development, have reduced the perceivedcommercial value of new drug development for IBS and limited
options for one of the most common GI disorder experienced by
patients and seen by physicians in clinical practice [4].
To meet the unmet need for safe and effective treatments for
IBS, the U.S. FDA’s Study Endpoint and Label Development group
has issued a patient-reported outcome (PRO) guidance document
[5] that specifies a multistage procedure for evaluating novel
agents by using valid and reliable PROs. The FDA regards IBS as
one of the top five medical conditions for which a PRO is urgently
needed. The process of developing a PRO begins with the
delineation of a conceptual framework that clearly describes
the relationship among what the PRO instrument is trying to
measure (concept), the core signs or symptoms specific to the
underlying disease or condition being assessed (domain), and the
individual items representative of aspects of the domains; pro-
ceeds with both qualitative and quantitative research to defineociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Fig. 1 – Conceptual framework of a patient reported outcome
instrument. Adapted from Clin Pharmacol Ther, 84(2), Burke LB,
Kennedy DL, Miskala PH, Papadopoulos EJ, Trentacosti AM. The
use of patient-reported outcome measures in the evaluation of
medical products for regulatory approval, 281-3, 2008, with
permission from Nature Publishing Group.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 9 7 – 1 0 398items reflecting those symptoms and establish their psycho-
metric properties; and culminates in the production of a PRO
measure that reflects therapeutic benefit from the patient’s
perspective. Historically, attempts to develop patient-reported
end points have gravitated toward the construct of perceived
severity of symptoms as a metric for gauging both illness status
and the benefit of novel treatments. Representative of this
approach is the IBS Symptom Severity Scale (IBS-SSS), a global
measure of IBS symptoms that aggregates patient ratings of
different, well-defined domains of IBS into a single overall score.
The IBS-SSS [6] has been recommended by the Rome Foundation
[7] as the global end point for measuring IBS symptom severity in
clinical trials. This scale asks individuals to rate four symptom
dimensions, each measured on a 0 to 100 rating scale: 1) the severity
of abdominal pain, 2) the severity of abdominal distention/tightness
(bloating), 3) satisfaction with bowel habits, and 4) life interference
due to IBS symptoms. A final item asks the number of days out of
previous 10 when the patient experiences abdominal pain, with the
answer multiplied by 10 to create a 0 to 100 metric for it.
Like other composite measures developed under the PRO
initiative [8], the IBS-SSS generates a total aggregate by summing
its items to derive an index of overall symptom severity. Combin-
ing items across multiple symptom domains for the purpose of
generating a global score is a common practice in PRO develop-
ment [9]. Theoretically, this approach maps onto the requisite
conceptual framework (see Fig. 1) the FDA recommends for
constructing a PRO instrument whose overarching measurement
focus (concept) is a product of multiple domains (e.g., signs and
symptoms). Methodologically, however, aggregating scores from
composite items potentiates at least two problems that can make
scales misleading. The first problem is aggregation bias. The
underlying mechanisms that impact one set of symptoms may
differ from the underlying mechanisms that impact another set
of symptoms. Aggregating across items obscures such dynamics.
One is left with a total score whereby component scores may
behave differently in response to a treatment or where the overall
score masks a relationship between a component symptom and
some other variable of clinical import. For example, a pharma-
cological treatment may impact defecatory symptoms but have
limited, if any, effect on abdominal pain or discomfort. An overall
score would then reflect a mixture of change on the item
associated with bowel habits and random or systematic ‘‘noise’’
due to the pain items. The result is an index that can mask the
true effects of the treatment or make it harder to detect those
effects. By the same token, a novel agent may provide some pain
relief but little, if any, benefit for defecatory symptoms. Anaggregate index will capture both the genuine therapeutic change
and the ‘‘noise’’ due to the other components measured by the
scale. Aggregation bias represents a serious threat to accurately
characterizing patients’ experience of their disease and asso-
ciated treatment, which is the penultimate goal of FDA’s PRO
guidance document [10].
A second problem is that variation in the total score, all else
being equal, is dominated by whichever subcomponent has the
most variability across people. If patients exhibit considerable
variation on the pain subscale but only modest variation on a
subscale about defecatory symptoms such as stool frequency, then
variations on the total score will primarily reflect variations in pain,
not bowel symptoms. Such a dynamic would advantage agents with
strong analgesic properties over those that are primarily designed to
relieve defecatory symptomswhen using the overall composite score
to evaluate a therapeutic agent. This is particularly germane to the
IBS-SSS because three of its five items tap abdominal pain or
discomfort (pain and bloating severity, number of pain days) and
thus likely contribute more variability to the total score. In effect, the
IBS-SSS ‘‘triple weights’’ items assessing abdominal pain/discomfort
over those assessing nonpain aspects of the IBS experience.
These issues are not necessarily problematic if individual
items comprising a multi-item scale are highly correlated and
unidimensional in nature. Unidimensional scales measure a
single dimension or group of dimensions that cluster with one
another. To the extent that a scale is unidimensional and items
are highly correlated, the behavior of one item parallels the
behavior of other items. The extent to which composite measures
of IBS (or for that matter other diseases) are unidimensional is thus
an important and largely overlooked psychometric matter critical to
the development of sound, meaningful, and sensitive PROs. To our
knowledge, IBS end points have been developed without regard to
documenting their unidimensional versus multidimensional prop-
erties. One purpose of the present study was to examine the
unidimensional versus multidimensional structure of the IBS-SSS.
To the extent that individual IBS symptoms are characterized
by both nontrivial unique and common variance, it can be useful
to identify symptom clusters that characterize significant num-
bers of patients with IBS. Different treatment regimens might
then be implemented depending on the observed symptom
patterns, with some therapeutic agents being more appropriate
for some types of patients but less appropriate for other types.
The present study applied cluster analytic methods to the core
symptoms measured by the IBS-SSS with the objective of identify-
ing distinct patient profiles that may require different approaches to
symptom resolution. In contrast to traditional approaches that treat
each symptom as a separate construct, person-centered cluster
analysis uses an idiographic approach that represents the presenta-
tion of multiple symptoms as an organized whole [11].Methods
Participants
Participants included 98 consecutively evaluated patients with
IBS recruited primarily through local media coverage and com-
munity advertising and referral by local physicians to a tertiary
care center at an academic medical center. To qualify, partici-
pants must have met Rome II IBS diagnostic criteria [12] without
organic GI disease (e.g., IBD and colon cancer) as determined by a
board-certified study gastroenterologist. Because this study was
conducted as part of a clinical trial for patients more severely
affected with IBS, participants must have also reported IBS
symptoms of at least moderate intensity (i.e., symptom occurring
at least twice weekly for 6 months and causing life interference).
Institutional review board approval and written, signed consent
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 9 7 – 1 0 3 99were obtained before the study began. This study was completed
in full compliance with the Declaration of Helsinki.
Procedure
After a brief telephone interview to determine whether partici-
pants were likely to meet basic inclusion criteria, participants
were scheduled for a medical examination to confirm IBS diag-
nosis [12,13] and psychometric testing, which for the purposes of
this study included the following test battery. Detailed informa-
tion about study procedure can be found elsewhere [14].
Measures
The IBS-SSS [6] is a five-item instrument used to measure
severity of abdominal pain, frequency of abdominal pain, severity
of abdominal distension, dissatisfaction with bowel habits, and
interference with quality of life on a 100-point scale. For four of
the items, the scales are represented as continuous lines with
end points 0% and 100%, with different descriptors at the end
points and adverb qualifiers (e.g., ‘‘not very,’’ ‘‘quite’’) strategically
placed along the line. Respondents mark a point on the line
reflecting the extremity of their judgment between the two end
points, and the proportional distance from zero is the score
assigned for that scale (hence scores range from 0 to 100). The
end points for the severity items are ‘‘no pain’’ and ‘‘very severe,’’
for satisfaction, the end points are ‘‘not at all satisfied’’ and ‘‘very
satisfied,’’ and for interference, they are ‘‘not at all interferes’’ to
‘‘completely interferes.’’ A final item asks the number of days out
of 10 the patient experiences abdominal pain, and the answer is
multiplied by 10 to create a 0 to 100 metric. The items were
summed, and thus the total score could range from 0 to 500. The
IBS-SSS was used as an end point of the clinical study fromwhich
secondary analyses were derived for this study.
We also obtained a single-item, global measure of symptom
severity by using the University of California at Los Angeles
Global Severity of Gastrointestinal Symptoms Scale. It [15] is a 21-
point rating scale where participants rate the overall severity of
their symptoms (where the specific symptoms are unspecified)
on a 0- (no symptoms) to 20- (most intense symptoms imagin-
able) point scale.
Data Analytic Plan
To place variables on a common metric and to ease interpretation
of some analyses, all measures were rescaled to a 0 to 10 metric.
This was accomplished by subtracting the lowest possible score
attainable for each variable from an individual’s observed score
and then dividing this by the highest possible score on that
variable. This result was then multiplied by 10. Thus, scores for
every variable range from 0 to 10, with a midpoint of 5. This
strategy represents a simple linear transformation that preserves
differential variability, differential central tendencies, and dis-
tributional forms for the variables, all while establishing a
common 0 to 10 metric. We first tested whether the five
component measures of the IBS-SSS behaved in accord with a
single-factor model (i.e., unidimensionality) by using confirma-
tory factor analysis based on maximum likelihood methods.
Once unidimensionality was rejected, we used exploratory factor
analysis to gain insights into the underlying dimensional struc-
ture of the scale, based on principal components extraction with
an oblimin rotation. The oblimin rotation permits the underlying
factors to be correlated, which seemed more theoretically com-
pelling than a varimax rotation. Finally, as described later, cluster
analysis of the measures was applied to the data using K-means
clustering algorithms, which are described below. This method of
analysis identifies clusters of individuals who show similar
profiles across the component symptoms but who have a distinctprofile relative to individuals in other clusters. The goal is to
classify individuals into categories, with each category contain-
ing individuals who are similar to each other and different from
individuals in other categories. Such an approach is useful in IBS
research where there is known heterogeneity in the complexion
of symptoms that characterize patients with a common syn-
drome. The K-means algorithm specifies a fixed number of
clusters, k, and assigns cases to clusters so that the means for
all variables are as different from each other as possible for the
different clusters. The value of k is determined through
successive solutions that increment the value of k by 1, with
the chosen solution being one that yields theoretically mean-
ingful cluster profiles that meaningfully increment estimates
of explained variance relative to solutions with smaller k and
whose cluster sizes are not trivial. Although it would have
been preferable to use more modern methods of classification
analysis, such as latent profile analysis, the sample size
was judged to be too small for such methods. As such, the
results reported here should be viewed as illustrative and
tentative.Results
Preliminary Analyses
There were minimal missing data, amounting to no more than a
few cases on most variables and representing less than 2% of the
cases. Missing values were imputed by using the Markov Chain
Monte Carlo method based on Schafer [16]. Nonnormality of the
variables was evaluated by computing values of skewness and
kurtosis. These values as well as the means and SDs of the
variables are presented in Table 1. We evaluated the data for
multivariate outliers by using a leverage statistic. An individual
was identified as an outlier if he or she had a leverage score four
times larger than the mean leverage index. No outliers were
identified.
The Unidimensionality of the IBS-SSS Measure
To determine whether the five component items of the IBS-SSS
are unidimensional in structure, a single-factor confirmatory
factor analysis model was fit to the 5  5 covariance matrix for
the items. The single-factor model yielded a poor fit to the data
(w2 with 5 degrees of freedom ¼ 19.99; P o 0.01; Comparative Fit
Index ¼ 0.80; Root Mean Square Error of Approximation ¼ 0.18; P
value for close fit o 0.01), suggesting a multidimensional struc-
ture. An exploratory factor analysis on the component measures
was performed by using principal components extraction and an
oblimin rotation. A two-factor solution was suggested by the
analysis, with the two pain and bloating items loading on one
abdominal pain/discomfort factor and the life interference and
satisfaction with bowel items loading on the second symptom
burden factor. Columns 2 through 6 of Table 2 present the 5  5
correlation matrix between the component measures as well as
the standardized factor loadings and standardized unique var-
iances for the two-factor solution. Even though a two-factor
model reasonably accounts for the correlations between the
measures, several of the individual measures have considerable
unique variance associated with them, independent of the two
common factors, ranging from about 25% to 50%. These data are
presented in Table 2. The presence of substantial unique variance
was even true of pain items, one of which taps the number
(frequency) of pain days and the other taps pain intensity. This
suggests that even forming two ‘‘total scores,’’ one for each of the
factors observed in the factor analysis, may obscure important
dynamics for some of the component measures in their own
Table 1 – Descriptive statistics.
Mean SD Skewness Kurtosis %
Female — — — — 88
Married — — — — 29
Employed full time — — — — 46
Graduating college — — — — 52
Age (y) 46.7 16.9 .03 .99
Months with IBS 197.8 184.0 1.05 .06
UCLA-SSS 5.49 2.03 .36 .35
IBS-SSS 5.97 1.54 .11 .29
Bowel subtypes
IBS-Diarrhea — — — — 41
IBS-Constipation — — — — 39
IBS-Mixed — — — — 18
Missing — — — — 2
Note. Untransformed mean for UCLA-SSS is 11.52 and for IBS-SSS it is 298.5.
IBS, irritable bowel syndrome; IBS-SSS, IBS Symptom Severity Scale; UCLA-SSS, University of California at Los Angeles Symptom
Severity Scale.
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symptoms. The estimated correlation between the factors
was 0.20.
Exploratory Cluster Analysis of Items of the IBS-SSS
Given the failure of unidimensionality for the IBS-SSS and the
pattern of correlations in Table 3, we conducted exploratory
cluster analyses on the items of the IBS-SS by using a K-means
clustering algorithm. A four-group solution was settled upon. The
cluster sizes and profile means on the five items are presented in
Table 3. All means are on a 0 to 10 metric, with 5 representing the
scale midpoint.
The first cluster of patients, representing about 25% of the
cases, is characterized by elevated scores on pain frequency and
bowel dissatisfaction, with somewhat less elevated but still high
mean scores on life interference. However, the pain severity
ratings tend to be low. The second cluster of patients, represent-
ing about 19% of the cases, is characterized by intermediate
scores on the pain dimensions, with somewhat more elevated
scores on bowel dissatisfaction. The third cluster of patients,
representing about 18% of the cases, is characterized by elevated
scores on all subcomponents. Finally, the fourth cluster of
patients, representing about 37% of the cases, has relatively low
scores on all dimensions except bowel dissatisfaction, with aTable 2 – Correlations between IBS-SSS component items, the
the items.
Correlations
Pain-
Severity
Pain-
Frequency
Bloating Bo
dissat
Total .76 .76 .66
Pain-Severity 1.00
Pain-Frequency .45 1.00
Bloating .53 .29 1.00
Bowel dissatisfaction .00 .23 .02 1
Interference .30 .25 .14
Notes. ‘‘Total’’ refers to the total score on the IBS-SSS scale; factor loading
proportion of variance in a measure unaccounted for by the two factors
IBS-SSS, irritable bowel syndrome Symptom Severity Scale.
* A statistically significant correlation, P o 0.05.somewhat elevated mean for life interference due to IBS
symptoms.
It is interesting to compare the four clusters on the overall
global ratings of symptom severity on the independently
assessed University of California at Los Angeles severity scale.
Table 3 shows, not surprisingly, that the mean global character-
ization of IBS symptom severity is highest for cluster 3 patients
who scored high on all IBS-SSS subscales and somewhat elevated
for cluster 1 and 2 patients.Variance Contributions of Individual Items to the Total Score
The first row of Table 2 presents the correlations between the
individual items of the IBS-SSS and the total IBS-SSS score. The
correlations are strongest for the two pain items. The squared
semipartial correlation between the two pain items and the total
score was 0.19 (holding the other items constant), suggesting that
the pain items uniquely account for 19% of the variation in the
total scores. The squared semipartial correlation for bloating and
the total score was 0.07, suggesting that it uniquely accounts for
7% of the variation in IBS-SSS scores. For bowel dissatisfaction,
the squared semipartial correlation was 0.05, suggesting that it
uniquely accounts for 5% of the variation in the IBS-SSS total
score, and for life interference, it was 0.04, suggesting that ittotal IBS-SSS score, and results of a factor analysis on
F1
Loading
F2
Loading
Unique
variance
wel
isfaction
Interference
.42 .57 — — —
.87 .17 .24
.65 .45 .48
.80 .02 .34
.00 .00 .85 .25
.35 1.00 .33 .75 .41
s are standardized; unique variances are standardized and reflect the
: F1 ¼ Factor 1, F2 ¼ Factor 2.
Table 3 – Profile means for K-means cluster analysis.
Cluster 1 Cluster 2 Cluster 3 Cluster 4
Pain-severity 3.97 5.01 7.28 1.75
Pain-frequency 9.22a 4.29 8.72a 3.27
Bloating 3.85a 6.11 7.53 2.97a
Bowel dissatisfaction 8.97a 7.16 8.94a 8.28a
Life interference 7.11a 6.61b 8.11a 6.34b
Percentage of cases 25.5 19.4 18.4 36.7
UCLA severity mean 5.56a 5.86a 7.19 4.41
Notes. Within a row, cluster means are statistically significantly different at Po 0.05 if they do not share a common superscript. The UCLA
severity scale was not a formal part of the cluster analysis. The mean values as a function of cluster are reported here for their interest value.
UCLA, University of California at Los Angeles.
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score. By using the logic of communality analysis [17], it was
found that 66% of the variation in the total score was due to
variance common to two or more of the items, whereas 34% of
the variation was unique to individual items independent of this
common variance.Discussion
The present study explored psychometric properties of a multi-
domain PRO scale, the commonly used IBS-SSS. Several interest-
ing results emerged.
First, we found that the multi-item IBS-SSS was not unidi-
mensional in character, but rather multidimensional. The indi-
vidual items were only moderately correlated with one another
and patterned themselves in accord with a two-factor/latent
variable model underlying their associational structure rather
than one. Although two latent variables can reasonably account
for the correlations between the component items, each compo-
nent was found to have nontrivial amounts of unique variance,
suggesting that each component probably should be treated
separately to avoid aggregation bias. For example, even though
pain frequency and pain intensity were correlated 0.45, the
estimated proportion of unique variance in each measure that
could not be accounted for by the common factors was 0.24 and
0.48, respectively. This item-specific unique variance is large
enough that these two facets of pain could respond differentially
to treatment or show differential associations to variables
designed to illuminate the mechanisms underlying IBS symp-
toms. At these early stages of theory development in IBS
research, it probably is judicious to keep such measures separate
and to empirically document their common versus unique
response to different treatment protocols rather than to collapse
them into an aggregate index that obscures possible differential
dynamics among component symptoms. One option is to adopt
coprimary end points reflecting the core symptoms that define
IBS (i.e., abdominal pain and bowel symptoms). Beyond issues of
sample size, trial costs, and drug development timelines, this
approach presumes that the two symptoms accurately capture
the patient’s experience (i.e., equally intense, bothersome, dis-
tressing, impactful). To be sure, some patients experience bowel
symptoms and pain as equally problematic. But for some
patients, abdominal pain or discomfort is the most clinically
significant IBS symptom, while for others, the illness is defined
by their bowel symptoms [18,19]. The assumption that the
clinical significance of IBS symptoms is necessarily uniform
across all patients runs the risk of imposing through end pointselection a value judgment on patients’ symptom experience. To
us, this would undermine a core principle of the PRO movement,
namely, incorporating into therapy development the patient’s
perspective on the impact of a disease and its treatment on his or
her functioning and well-being. An alternative approach based
on the recently released FDA guidance [20] is to calibrate the
selection of end points to the target symptom and its putative
mechanism of action; for example, drugs that target abdominal
pain would use a single end point of pain intensity.
Of course, if one’s goal is merely to document a consistently
low score across all symptoms without concern for the different
mechanisms that can produce moderate to high scores, then
aggregating across the diverse items can be justified. However,
aggregating items that are multidimensional in structure carries
a realistic risk of introducing a degree of noise that makes it
difficult to understand the patients’ experience and detect treat-
ment effects. This is particularly problematic for agents that
differentially impact different aspects of a given disease ‘‘where
the intention is not necessarily to cure but to ameliorate symp-
toms, facilitate functioning, or improve quality of life’’ [8]. For
these reasons, we believe that such practices are not conducive to
building an informative and useful knowledge base surrounding
IBS [21]. Nor will it lend itself to characterizing precisely the
therapeutic benefit of novel agents for specific symptoms. In our
opinion, it is preferable to distinguish between the different
components defining IBS symptom severity and to model these
components separately or multivariately, such as in a person-
centered approach.
To this end, we conducted an exploratory cluster analysis of
the five symptom items of the IBS-SSS to identify meaningful,
distinct patient profiles on the basis of their IBS-SSS responses.
We found evidence for four discrete patient subtypes or profiles.
One cluster of patients (25%) was characterized by elevated
scores on pain frequency and bowel dissatisfaction, with some-
what less elevated but still high mean scores on life interference.
The pain severity ratings, however, tended to be relatively low.
Although these patients do not report severe pain, what pain they
experience is persistent and a source of moderate life interfer-
ence. A second cluster of patients (19%) was characterized by
intermediate scores on the pain dimensions, but with more
elevated scores on bowel dissatisfaction. These patients seem
to endure IBS without experiencing the levels of pain of other
groups of patients, but their symptoms take a toll on their well-
being. A third cluster of patients (18%) had elevated scores on all
subcomponents of the IBS-SSS. Finally, the fourth and the most
common cluster of patients (37%) had relatively low scores on all
dimensions except dissatisfaction with bowels and, to a lesser
extent, IBS interfering with one’s life. Interestingly, the mean
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 9 7 – 1 0 3102global characterization of IBS symptom severity was highest for
cluster 3 patients, lowest for cluster 4 patients, and somewhat
elevated for cluster 1 and 2 patients. This analysis, of course, was
based on a relatively small sample and a restricted population
from a single investigative team, and so it must be interpreted
judiciously. However, future research might benefit from adapt-
ing a person-centered approach to data analysis to characterize
common combinations of IBS symptoms. Both the factor ana-
lyses and the cluster analyses underscore the utility of differ-
entiating rather than aggregating symptom dimensions.
Clinically, these data have important implications. Classifying
patients into subgroups on the basis of features they share may
expand our understanding of a disorder marked by dramatic
heterogeneity. To date, the Rome criteria are the most sophisti-
cated mechanism for making sense of the clinical diversity of IBS
[12]. The goals of Rome criteria, like any classification system, are
identifying common features within groups of individuals
(within-group homogeneity) and identifying differences with
groups of individuals (between-group heterogeneity). The nomo-
thetic focus of any diagnostic system means that it is concerned
with the grouping of individuals not heterogeneity within these
groups (within-group heterogeneity). As such, it is often assumed
that once subjects have been assigned a diagnostic label (e.g., met
Rome criteria for IBS) they are sufficiently similar to be randomly
assigned to treatment arms to determine the efficacy of a novel
agent. The tacit assumption that all patients with a given
disorder are one homogeneous group—what is referred to as
the patient uniformity myth [22]—is intrinsic to most clinical
research that features randomized clinical trials. But just because
patients enrolled into a clinical trial satisfy diagnostic criteria
does not necessarily mean that they suffer from the same set of
problems any more than family members who share the same
surname have identical attributes. Not all patients diagnosed
with IBS are the same. The severity and complexion of their
symptoms, underlying pathophysiology, and treatment goals
(e.g., pain reduction, bowel symptom relief) differ often drama-
tically between patients. Assigning a diagnostic label links indi-
viduals of a heterogeneous population on the basis of shared
clinical attributes, but it does not ‘‘homogenize’’ pathogenic
processes, diverse symptom dimensions, or patients’ treatment
goals. We are not confident that global end points (e.g., adequate
relief, IBS-SSS, and composite symptom severity scores) are
psychometrically sound enough to correct for the within-group
heterogeneity that characterizes patients with IBS of so many
different stripes. Indeed, there are some reasons to believe that
they may actually introduce error variance that makes it more
difficult to detect the beneficial effect of therapy [23]. Disregard-
ing individual differences that make up the symptom topography
of patients who share a diagnostic label may very well explain
why so many studies testing the therapeutic benefit of novel
agents yield disappointing results. Peripherally acting therapies
for IBS have demonstrated partial efficacy at best with numbers
needed to treat in the double digits [24]. Central nervous system
pharmacotherapies that have proven efficacious for non-GI pain
disorders [25,26] have a disappointing track record with IBS in
spite of a growing body of evidence highlighting the abnormal
pain processing pathways in IBS [27].
Our data raise the question of whether meaningful conclu-
sions regarding the therapeutic benefit of a given therapy can be
confidently drawn until patient heterogeneity is recognized and
factored into the design and interpretation of randomized con-
trolled trials. If not, then researchers would be wise to move
beyond the ‘‘horserace’’ questions of does treatment X work
better than Y for patients with a shared diagnosis and confront
the question of what treatments produce what changes for which
kind of symptoms [21]. Establishing subtypes of IBS may help
develop more targeted, effective interventions that are calibratedto the symptoms for which patients seek relief not the diagnosis
they have been assigned. For an illness as heterogeneous as IBS, a
claim based on diagnosis confers little information about the
specific symptoms for which a treatment is beneficial. A more
tailored approach may optimize treatment benefits, minimize
harms, and conserve the use of limited health resources. The
process of subgrouping patients may yield indirect benefits to
physicians and their patients. Because unrecognized heteroge-
neity among patients can undermine the power of a randomized
trial to detect a truly beneficial treatment [28,29], efforts to
systematically minimize heterogeneity may help accelerate the
development of novel agents and index more accurately their
genuine treatment effects that differences among study partici-
pants may obscure. This may in the long term improve the
quality of care and reduce the disease burden of IBS.
The results of this study are by no means the last or first word
on subtyping patients with IBS. Previous efforts to delineate IBS
subgroups have focused on patterns of symptoms (e.g., predo-
minant bowel type), their severity, visceral hyperalgesia, intest-
inal transit, psychological distress, and illness behaviors [30–37].
We chose to use the IBS-SSS as a basis for subtyping because the
Rome Foundation recommends it as an end point in clinical trials
[7]. That said, we understand that its scope is limited to subjective
complaints. Other factors that make up the multifactorial puzzle of
IBS include gut-related dysfunctions (motility, secretion, immune
function, permeability) as well as brain-related alterations, including
increased stress reactivity[38], impaired coping styles [23], and
selective attention to threat and symptom-related fears [39]. Further
research that integrates the biobehavioral variables and instruments
(PROs, biological assessments) that define a subgroup scheme with
the greatest clinical and research utility is urgently needed.
The results of the present research, of course, must be
interpreted in light of limitations. The sample is relatively small
and representative of only a single clinic in an academic medical
center located in the northeast. Because the measures of all
constructs were based on self-report data, they are subject to
some bias and measurement error, which can bias parameter
estimates. K-means classification algorithms are less than opti-
mal, but we could not use more advanced latent class analyses
because of sample size restrictions. Because this is a cross-
sectional study, data were collected at a single point in time. In
light of research showing that subtyping of bowel habits among a
significant proportion of patients with IBS changes over time [40],
it will be important to determine the temporal stability of
subtyping derived from the IBS-SSS using longitudinal research
designs. Despite such limitations, the results of the research are
interesting and set the stage for more refined empirical work on
the important issues identified. The research suggests the need
to distinguish between different GI symptoms defining IBS
severity, without obscuring matters through aggregation into
total scores unless unidimensionality can be first demonstrated.
This is an empirical question that demands more than leaps of
faith to heed the FDA’s call for quality PROs. Even if there is
evidence of unidimensionality, if one or more of the individual
items has large amounts of unique variance, then, averaging
items relegates the unique features of a single symptom to error
variance and diverts attention from what might be clinically
meaningful facets of patients’ experience of IBS. These are
weighty psychometric issues. In the end, attention to these
important maters will go a long way in creating an empirically
sound, meaningful, and clinically useful PRO that is sensitive to
the treatment effects of agents for IBS and other disease states
whose symptoms lack a reliable biomarker and are best under-
stood from the patient perspective.
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